CLINICAL TRIALS PROFILE FOR IOBENGUANE I-131
✉ Email this page to a colleague
All Clinical Trials for Iobenguane I-131
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00126412 ↗ | Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma | Completed | GE Healthcare | Phase 3 | 2005-08-02 | The study is designed to study the effectiveness of 123I-mIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroblastoma or phaeochromocytoma. |
| NCT00126425 ↗ | Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease | Completed | GE Healthcare | Phase 3 | 2005-07-01 | The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to predict cardiac outcomes in subjects with heart failure and in comparison to subjects without cardiovascular disease. |
| NCT00126438 ↗ | Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease | Completed | GE Healthcare | Phase 3 | 2005-07-01 | The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to predict cardiac outcome in subjects with heart failure and in comparison to subjects without cardiovascular disease. |
| NCT00339131 ↗ | ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid | Completed | Molecular Insight Pharmaceuticals, Inc. | Phase 1 | 2006-06-01 | The purpose of this study is to test the safety of a drug called Ultratrace iobenguane I 131 that has radioactivity, to measure how long it takes for the drug to be absorbed and passed out of the body, and to measure how much radioactivity is absorbed into different tissues of the body. |
| NCT00458952 ↗ | Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma | Completed | Molecular Insight Pharmaceuticals, Inc. | Phase 1/Phase 2 | 2007-04-01 | The purpose of this study is to determine whether iobenguane I 131 is safe and effective in patients with malignant pheochromocytoma or paraganglioma. |
| NCT00659984 ↗ | N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma | Completed | Molecular Insight Pharmaceuticals, Inc. | Phase 2 | 2008-06-01 | RATIONALE: Radioactive drugs, such as iodine I 131 metaiodobenzylguanidine (MIBG), may carry radiation directly to tumor cells and not harm normal cells. A bone marrow or peripheral stem cell transplant using stem cells from the patient may be able to replace blood-forming cells that were destroyed by I 131 MIBG. PURPOSE: This phase II trial is studying the side effects and best dose of iodine I 131 MIBG followed by a stem cell transplant in treating young patients with relapsed or refractory high-risk neuroblastoma. |
| NCT00730444 ↗ | Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma | Approved for marketing | GE Healthcare | 1969-12-31 | GE Healthcare has recently submitted a New Drug Application (NDA) for Iobenguane I 123 Injection ([123I]mIBG (AdreView)) as a diagnostic nuclear imaging agent for the detection of primary or metastatic neuroblastoma and pheochromocytoma. The present protocol establishes an Expanded Access program to provide AdreView to pediatric medical centers and hospitals that treat neuroblastoma patients. AdreView will be provided for use in diagnostic assessment of patients with known or suspected neuroblastoma for whom there is an appropriate clinical indication for [123I]mIBG imaging. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Iobenguane I-131
Condition Name
Clinical Trial Locations for Iobenguane I-131
Trials by Country
Clinical Trial Progress for Iobenguane I-131
Clinical Trial Phase
Clinical Trial Sponsors for Iobenguane I-131
Sponsor Name
